

02-19-03

1646

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number 09/995,225

Filing Date November 26, 2001

First Named Inventor Chen

Group Art Unit 1646

Examiner Name Not Yet Assigned

Attorney Docket Number 21.US18.CIP(formerly AREN-0308)

Total Number of Pages in This Submission

20

RECEIVED

FEB 20 2003

TECH CENTER 1600/2900**ENCLOSURES (check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Response☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/
Incomplete Application☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53☐ Assignment Papers
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s)☐ After Allowance Communication to
Group☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s)
(please identify below):**Request for Corrected
Application Publication with
attachments**

Remarks

VIA EXPRESS MAIL LABEL NO.: EV146607355US**DATE: FEBRUARY 14, 2003****SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm
or
Individual name

Michael P. Straher, Registration No.: 38,325

Signature



Date

February 14, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EV146607355US addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: February 14, 2003

Typed or printed name

Michael P. Straher

Signature



Date

February 14, 2003

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DOCKET NO: 21.US18.CIP/AREN-0308

PATENT



RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 20 2003

TECH CENTER 1600/2900

In Re Application of: Chen et al.

Confirmation No.: 1454

Serial No.: 09/995,225

Group Art Unit: 1646

118

Filing Date: November 26, 2001

Examiner: Not Yet Assigned

Publication No.: US 2002/0193584-A1

Publication Date: December 19, 2002

For: ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G PROTEIN-
COUPLED RECEPTORS

Via Express Mail Label No. EV 146607355 US
Date of Deposit: February 14, 2003

Box PG Pub
Commissioner for Patents
Washington, DC 20231

REQUEST FOR CORRECTED APPLICATION PUBLICATION

Applicants respectfully request that the following corrections be made to Publication No.:
US 2002/0193584-A1, published on December 19, 2002. Each of the proposed corrections are
necessitated by printing errors made by the PTO. Accordingly, no fee is required.

Printing Errors in Table E

On page 16 of the published application, in Table E, please make the corrections
indicated on the attached marked-up version of page 16. These errors are believed to be material
to understanding the 3' and 5' primer sequences, cycle conditions, and tissue expression location
of the hRUP29 and hRUP31 receptors shown in Table E. Copies of corresponding pages 52 and

53 of the specification as filed (Ser. No. 09/995,225), showing Table E as filed, also have been provided.

Substitution of G_1 for G_i :

Applicants respectfully request correction of the following additional PTO printing errors in the published application.

On page 2 of the published application, in the second line of paragraph [0030], please replace " $G_q(\text{del})/G_1$ " with " $G_q(\text{del})/G_i$ ".

On page 6 of the published application, in the first line of paragraph [0082], please replace " G_1 " with " G_i ".

On page 6 of the published application, in the seventh line of paragraph [0082], please replace " G_1 " with " G_i ".

On page 7 of the published application, in the fifteenth line of paragraph [0090], please replace " G_1 " with " G_i ".

On page 8 of the published application, in the sixth line of paragraph [0094], please replace " G_1 " with " G_i ".

On page 13 of the published application, in the twenty-second line of paragraph [0188], please replace " G_1 " with " G_i ".


On page 15 of the published application, in the fourth line of paragraph [0202], please replace " $G_q(\text{del})/G_1$ " with " $G_q(\text{del})/G_i$ ".

On page 15 of the published application, in the twelfth line of paragraph [0202], please replace " $G_q(\text{del})/G_1$ " with " $G_q(\text{del})/G_i$ ".

Copies of pages 2, 6, 7, 8, 13 and 15 of the published application, and the corresponding pages of the 09/995,225 application, showing the location of the errors, are also provided.

Respectfully Submitted,

Date: February 14, 2003



Michael P. Straher
Registration No.: 38,325

Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
Telephone: (215) 665-2000
Facsimile: (215) 665-2013



TABLE E

Receptor Identifier	Cycle Conditions (Min), Sec (") Cycles 2-4 repeated 35 times	5'Primer (SEQ.ID.NO.)	3'Primer (SEQ.ID.NO.)	DNA Fragment	Tissue Expression
hRUP28	94° C. for 5 min; 94° C. for 30 sec; 58° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	GTCCTCACT GGTGGCCAT GTACTCC (52)	CTGCGTCCAC CAGAGTCAC GTCTCC (53)	710 bp	heart; kidney; liver; lung and pancreas
hRUP29	94° C. for 5 min; 94° C. for 30 sec; 58° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	GTTTGTGGCT CTTPGGATGTT TGGGCTGCC CTTPCTGC (54)	AACGGCACA AAACACAAAT TCC (55)	690 bp	leukocyte and ovary
hRUP30	94° C. for 2 min; 94° C. for 15 sec; 58° C. for 20 sec; 72° C. for 1 min, and 72° C. for 10 min	CTGCTCACG GTTGACCGC TACACTGC (56)	GTGGCCATG AGCCACCCT GAGCTCC (57)	690 bp	pancreas
hRUP31	95° C. for 4 min; 95° C. for 1 min; 52° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	CTTCTTCTCC GACGTCAAG ATCG (58)	CCAAATCA GTGTGCAA GTGTGCAA (59)	516 bp	colon, lung, pancreas, thymus; cerebral cortex, hippocampus of brain, and fat cells
hRUP32	95° C. for 4 min; 95° C. for 1 min; 52° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	TGAATGGGT CCTGTGTGA AA (60)	CAACGGTCT GACAACCTC CT (61)	527 bp	thymus
hRUP34	95° C. for 4 min; 95° C. for 1 min; 52° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	TTGCTGTGAT GTGGCATTCT G (62)	CAGGAAGCC CATAAAGGC ATCAA (63)	534 bp	peripheral blood leukocyte ("PBL"), prostate and kidney
hRUP35	95° C. for 4 min; 95° C. for 1 min; 52° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	ACATCACCT GCTTCCTGA CC (64)	CCAGCATCTT GATGCAGTG T (65)	557 bp	thalamus
hRUP37	95° C. for 4 min; 95° C. for 1 min; 52° C. for 30 sec; 72° C. for 1 min, and 72° C. for 7 min	CCATCTCCA AAATCCTCA GTC (66)	GCTGTTAAG AGCGGACAG GAAA (67)	517 bp	testis, cerebral cortex and hippocampus

[0214] Diseases and disorders related to receptors located in these tissues or regions include, but are not limited to, cardiac disorders and diseases (e.g. thrombosis, myocardial infarction; atherosclerosis; cardiomyopathies); kidney disease/disorders (e.g., renal failure; renal tubular acidosis; renal glycosuria; nephrogenic diabetes insipidus; cystinuria; polycystic kidney disease); eosinophilia; leukocytosis; leukopenia; ovarian cancer; sexual dysfunction; polycystic ovarian syndrome; pancreatitis and pancreatic cancer; irritable bowel syndrome; colon cancer; Crohn's disease; ulcerative colitis; diverticulitis; Chronic Obstructive Pulmonary Disease (COPD); Cystic Fibrosis; pneumonia; pulmonary

hypertension; tuberculosis and lung cancer; Parkinson's disease; movement disorders and ataxias; learning and memory disorders; eating disorders (e.g., anorexia; bulimia, etc.); obesity; cancers; thymoma; myasthenia gravis; circulatory disorders; prostate cancer; prostatitis; kidney disease/disorders (e.g., renal failure; renal tubular acidosis; renal glycosuria; nephrogenic diabetes insipidus; cystinuria; polycystic kidney disease); sensorimotor processing and arousal disorders; obsessive-compulsive disorders; testicular cancer; priapism; prostatitis; hernia; endocrine disorders; sexual dysfunction; allergies; depression; psychotic disorders; migraine; reflux; schizophrenia; ulcers; bronchospasm; epi-

lists the receptors, the cycle conditions and the primers utilized, and also lists exemplary diseases/disorders linked to the receptors.

TABLE E

Receptor Identifier	Cycle Conditions Min ('), Sec (") Cycles 2-4 repeated 35 times	5' Primer (SEQ.ID.NO.)	3' Primer (SEQ.ID.NO.)	DNA Fragment	Tissue Expression
hRUP28	94°C for 5 min; 94°C for 30 sec; 58°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	GTCCTCACT GGTGGCCAT GTACTCC (52)	CTGCGTCCAC CAGAGTCAC GTCTCC (53)	710bp	heart; kidney; liver; lung and pancreas
hRUP29	94°C for 5 min; 94°C for 30 sec; 58°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	CTTGGATGTT TGGGCTGCC CTTCTGC (54)	GTTTGTGGCT AACGGCACA AAACACAAT TCC (55)	690bp	leukocyte and ovary
hRUP30	94°C for 2 min; 94°C for 15 sec; 58°C for 20 sec, 72°C for 1 min, and 72°C for 10 min	CTGCTCACG GTTGACCGC TAACTGC (56)	GTGGCCATG AGCCACCCT GAGCTCC (57)	690bp	pancreas
hRUP31	95°C for 4 min; 95°C for 1 min; 52°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	CTTCTTCTCC GACGTCAAG G (58)	CCAAATCA GTGTGCAA ATCG (59)	516bp	colon, lung, pancreas, thymus; cerebral cortex, hippocampus of brain, and fat cells
hRUP32	95°C for 4 min; 95°C for 1 min; 52°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	TGAATGGGT CCTGTGTGA AA (60)	CAACGGTCT GACAACCTC CT (61)	527bp	thymus
hRUP34	95°C for 4 min; 95°C for 1 min; 52°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	TTGCTGTGAT GTGGCATT G (62)	CAGGAAGCC CATAAAGGC ATCAA (63)	534bp	peripheral blood leukocyte ("PBL"), prostate and kidney
hRUP35	95°C for 4 min; 95°C for 1 min; 52°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	ACATCACCT GCTTCCTGA CC (64)	CCAGCATCTT GATGCAGTG T (65)	557bp	thalamus

hRUP37	95°C for 4 min; 95°C for 1 min; 52°C for 30 sec, 72°C for 1 min, and 72°C for 7 min	CCATCTCCA AAATCCTCA GTC (66)	GCTGTTAAG AGCGGACAG GAAA (67)	517bp	testis, cerebral cortex and hippocampus
--------	--	------------------------------------	-------------------------------------	-------	--

Diseases and disorders related to receptors located in these tissues or regions include, but are not limited to, cardiac disorders and diseases (e.g. thrombosis, myocardial infarction; atherosclerosis; cardiomyopathies); kidney disease/disorders (e.g., renal failure; renal tubular acidosis; renal glycosuria; nephrogenic diabetes insipidus; cystinuria; polycystic kidney disease); eosinophilia; leukocytosis; leukopenia; ovarian cancer; sexual dysfunction; polycystic ovarian syndrome; pancreatitis and pancreatic cancer; irritable bowel syndrome; colon cancer; Crohn's disease; ulcerative colitis; diverticulitis; Chronic Obstructive Pulmonary Disease (COPD); Cystic Fibrosis; pneumonia; pulmonary hypertension; tuberculosis and lung cancer; Parkinson's disease; movement disorders and ataxias; learning and memory disorders; eating disorders (e.g., anorexia; bulimia, etc.); obesity; cancers; thymoma; myasthenia gravis; circulatory disorders; prostate cancer; prostatitis; kidney disease/disorders(e.g., renal failure; renal tubular acidosis; renal glycosuria; nephrogenic diabetes insipidus; cystinuria; polycystic kidney disease); sensorimotor processing and arousal disorders; obsessive-compulsive disorders; testicular cancer; priapism; prostatitis; hernia; endocrine disorders; sexual dysfunction; allergies; depression; psychotic disorders; migraine; reflux; schizophrenia; ulcers; bronchospasm; epilepsy; prostatic hypertrophy; anxiety; rhinitis; angina; and glaucoma. Accordingly, the methods of the present invention may also be useful in the diagnosis and/or treatment of these and other diseases and disorders.

Example 7

Protocol: Direct Identification of Inverse Agonists and Agonists

A. [³⁵S]GTPγS Assay